Esophageal squamous cell carcinoma (ESCC) remains a formidable global health challenge, marked by high fatality rates predominantly driven by aggressive tumor proliferation and metastatic spread occurring often before diagnosis. Despite advancements in therapeutic strategies, the molecular underpinnings orchestrating ESCC progression are not yet fully elucidated, hindering the development of effective targeted interventions. Recent breakthrough research from leading Chinese institutions has shed new light on this critical issue by identifying a pivotal molecular axis involving TGIF2, HMGB3, TLR3, and TGF-β, which collectively drive ESCC malignancy.
This study centers on high-mobility group box 3 (HMGB3), a non-histone chromatin-binding protein increasingly implicated in cancer biology. The researchers discovered that HMGB3 expression is significantly upregulated in ESCC tissue samples and cell lines compared to normal counterparts, with quantitative PCR analyses revealing pronounced overexpression that correlates strongly with poor clinical prognosis. Western blotting and immunohistochemistry further confirmed elevated HMGB3 protein levels, establishing it as a biomarker linked to aggressive tumor behavior and unfavorable patient outcomes.
Diving deeper into the mechanistic aspects, the team identified TGIF2, a known transcriptional regulator, as an upstream activator directly binding to a specific promoter region of the HMGB3 gene (between -1138 bp and -894 bp). This interaction initiates a robust transcriptional upregulation of HMGB3. Intriguingly, the epidermal growth factor receptor (EGFR) signaling pathway modulates this process: activation by epidermal growth factor (EGF) triggers TGIF2 phosphorylation, which then enhances HMGB3 expression, a phenomenon reversible by the EGFR inhibitor gefitinib. These findings delineate a tightly controlled oncogenic signaling cascade, integrating extracellular stimuli into nuclear transcriptional responses.
Functionally, HMGB3 drives ESCC tumorigenesis by promoting cellular proliferation, migration, and invasion. Overexpression experiments demonstrated enhanced cell cycle progression, notably accelerating transition through G1 and S phases, which underpins rapid tumor cell propagation. Colony formation assays and real-time proliferation metrics such as CCK-8 further validated HMGB3’s role in fostering malignant growth. Concurrently, silencing HMGB3 markedly suppressed these phenotypes, indicating its necessity for maintaining the aggressive tumor phenotype.
A particularly novel insight emerged from the molecular interplay between HMGB3 and Toll-like receptor 3 (TLR3). The study revealed that HMGB3 physically interacts with TLR3 at specific amino acid residues (GLU-576, THR-710, VAL-720), forming a functional complex that potentiates downstream NF-κB signaling. Activation of NF-κB was evidenced by increased phosphorylation and nuclear translocation of the p65 subunit, which in turn transcriptionally induces both TGF-β and TLR3 expression. This positive feedback loop ensures persistent inflammatory and oncogenic signaling conducive to tumor progression.
Moreover, HMGB3’s influence extends to chromatin landscape remodeling, as demonstrated by ATAC-seq analyses which highlighted altered chromatin accessibility at the promoters of crucial TGF-β signaling pathway components, including TGF-β receptors and SMAD family members. This epigenetic modulation signifies a multi-layered regulatory role for HMGB3, bridging direct protein interactions with higher-order chromatin architecture changes that sustain oncogenic transcriptional programs.
The downstream consequences of this regulatory axis involve smad-dependent TGF-β signaling, a pathway widely recognized for its dual role in cancer. In ESCC, however, the study identifies this pathway as chiefly facilitating tumor growth and metastasis under the influence of TGIF2-HMGB3 activity. The convergence of TLR3/NF-κB inflammatory signals with TGF-β/Smad developmental pathways exemplifies a cooperative molecular framework driving malignancy, strengthening the rationale for targeting these intertwined nodes therapeutically.
Translational relevance was rigorously addressed by validating the TGIF2-HMGB3-TGF-β axis in independent patient cohorts, wherein co-expression levels of these factors robustly predicted poorer survival outcomes. Multivariate Cox regression further established their independent prognostic value, underscoring them as potential biomarkers not only for prognosis but also for guiding personalized treatment strategies in ESCC patients.
Complementing clinical correlations, patient-derived organoid models provided a preclinical platform to test therapeutic targeting, revealing that knockdown of TGIF2 or HMGB3 significantly attenuated tumor growth ex vivo. This result highlights the therapeutic promise of disrupting this axis and opens avenues for developing novel inhibitors or combination therapies aimed at these molecular targets.
The researchers also investigated potential interventional strategies. The application of a TGF-β-neutralizing antibody (1D11) and NF-κB pathway inhibitor (BAY 11-7082) effectively curtailed ESCC proliferation and metastasis, supporting the therapeutic viability of this approach. Importantly, inhibition strategies that block EGFR-mediated TGIF2 phosphorylation or HMGB3 function represent viable routes to interrupting this oncogenic cascade.
Despite significant advancements, the study acknowledges unresolved complexities. The precise molecular mechanisms by which HMGB3 simultaneously modulates chromatin remodeling and protein interactions within the TGF-β pathway remain elusive. Additionally, the impact of this signaling axis on the tumor microenvironment and immune cell infiltration warrants comprehensive exploration to understand the broader implications of targeted therapies.
Future investigations must address these gaps, with expanded cohorts for clinical validation and single-cell sequencing technologies to dissect cellular heterogeneity and lineage-specific signaling dynamics. Such efforts will be critical to refine personalized therapeutic regimens that effectively disrupt the TGIF2/HMGB3/TLR3/TGF-β network in ESCC, aiming to improve patient survival and quality of life.
In summary, this pioneering research delineates a novel oncogenic signaling nexus involving TGIF2, HMGB3, TLR3, and TGF-β, elucidating a multifaceted regulatory paradigm that integrates transcriptional control, signal transduction, and chromatin architecture modifications. The identification of this axis as a driver of ESCC proliferation and metastasis offers a promising foundation for the development of targeted molecular therapies, ultimately fostering improved clinical outcomes in this devastating cancer.
Subject of Research: Molecular mechanisms driving esophageal squamous cell carcinoma progression.
Article Title: TGIF2-mediated HMGB3 overexpression promotes esophageal squamous cell carcinoma proliferation and metastasis through TLR3/TGF-β signaling.
News Publication Date: [Not specified in the source content]
Web References: http://dx.doi.org/10.1016/j.gendis.2025.101987, https://www.sciencedirect.com/journal/genes-and-diseases
References: Original research article published in Genes & Diseases.
Image Credits: Liaoran Niu, Wanli Yang, Wei Zhou, Lili Duan, Qi Wang, Xiaoqian Wang, Yiding Li, Chengchao Xu, Yujie Zhang, Jinqiang Liu, Jian Zhang, Daiming Fan, Jianyong Zheng, Liu Hong
Keywords: Esophageal squamous cell carcinoma, HMGB3, TGIF2, TLR3, TGF-β signaling, NF-κB, EGFR, chromatin remodeling, metastasis, cancer proliferation, therapeutic targeting
